Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
about
Targeting of tolerogenic dendritic cells towards heat shock proteins: a novel therapeutic strategy for autoimmune diseases?T Cell-Mediated Chronic Inflammatory Diseases Are Candidates for Therapeutic Tolerance Induction with Heat Shock Proteins.Extracellular cell stress (heat shock) proteins-immune responses and disease: an overview.
P2860
Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Safety and patient response as ...... trial in rheumatoid arthritis.
@en
Safety and patient response as ...... trial in rheumatoid arthritis.
@nl
type
label
Safety and patient response as ...... trial in rheumatoid arthritis.
@en
Safety and patient response as ...... trial in rheumatoid arthritis.
@nl
prefLabel
Safety and patient response as ...... trial in rheumatoid arthritis.
@en
Safety and patient response as ...... trial in rheumatoid arthritis.
@nl
P2093
P2860
P356
P1433
P1476
Safety and patient response as ...... trial in rheumatoid arthritis
@en
P2093
Alexandra Vincent
Bruce Kirkham
Elizabeth Allen
Gabriel S Panayi
Joana C Vasconcelos
Khaldoun Chaabo
Timothy Mant
Toby Garrood
Valerie M Corrigall
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEW287
P577
2016-08-07T00:00:00Z